Charles River Laboratories International, Inc.

NYSE:CRL

Medical - Diagnostics & Research

Healthcare
$333.25 -1.33%

-$2.45 today

Market cap
$15.97B
Beta
1.45
P/E (TTM)
-48.3
EPS (TTM)
-$3.77
52W Low $144.26High $228.88

Volume 0.52M

Average 0.86M

CRL Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Charles River Laboratories International, Inc.NYSE: CRL

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income grows, but more slowly than its trailing trend

Q2 FY2026 operating income of $119.89M rose 19.7% year over year, behind the +296.6% change in trailing-twelve-month operating income. Sequentially, it fell 0.0% from the prior quarter. Over 3 fiscal years it compounded at -7.9% a year.

Context

  • Operating income amounted to 12.6% of revenue in FY2025, up 7.0 pp from a year earlier.
  • Operating income increased in 1 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 10 analysts of $926.37M (+82.4%) for the fiscal year ending Dec 2026, a slowdown from the +123.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$119.89M-0.0% QoQ
Last fiscal yearDec 2025
$507.84M+123.4% YoY
LTMJun 2026
$493.8M+296.6% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.7%+74.6%+54.9 pp
1 year+123.4%+82.4%-41.0 pp
3-year CAGR-7.9%+30.7%+38.6 pp
5-year CAGR+22.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
507.84M USD
Year-over-year change
+123.4%
4-year CAGR
-3.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How CRL compares with its peers on the latest reported figures

  • CRL's LTM Jun 2026 operating income of $493.8M is the 3rd highest of the 4 companies compared; the peer median is $607.14M.
  • Its year-over-year change of +296.6% is the highest of 4, against a peer median of +19.7%.
  • Operating income amounts to 12.3% of revenue for CRL, versus a peer median of 10.1%.
CRL Competitors Peer median
Operating Income for CRL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ICLRICON Public Limited CompanyLTM Jun 2026$837.6M -17.2%+8.4%10.1%
MEDPMedpace Holdings, Inc.LTM Sep 2026$607.14M +19.7%+24.3%21.4%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$493.8M +296.6%-7.9%12.3%
CERTCertara, Inc.LTM Mar 2026$17.34M +141.6%-13.5%4.1%
Peer median (excluding CRL) $607.14M+19.7%+8.4%10.1%

Competitors are the stored peer set for CRL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.54B3.98B4.13B4.05B4.02B
Cost of Revenue2.21B2.51B2.63B2.72B2.79B
Gross Profit1.33B1.46B1.5B1.33B1.23B
Gross Margin37.7%36.8%36.4%32.9%30.5%
Research & Development00000
Selling, General & Admin619.92M665.1M747.86M751M743.07M
Operating Expenses744.78M811.68M885.3M1.1B717.73M
Depreciation & Amortization265.54M303.87M314.12M361.74M403.31M
EBITDA820.16M986.15M1.03B581.14M410.84M
EBITDA Margin23.2%24.8%25.0%14.3%10.2%
Operating Income589.86M650.98M617.26M227.35M507.84M
Operating Margin16.7%16.4%14.9%5.6%12.6%
Interest Income652K780K5.2M8.58M4.94M
Interest Expense73.91M59.29M136.71M126.29M107.03M
Other Income / Expenses(109.15M)(27.99M)(35.98M)(134.23M)(607.34M)
Income Before Tax480.71M622.99M581.28M93.11M(99.5M)
Pre-Tax Margin13.6%15.7%14.1%2.3%-2.5%
Income Tax Expense81.87M130.38M100.91M67.82M42.66M
Net Income390.98M486.23M474.62M10.3M(144.34M)
Net Margin11.0%12.2%11.5%0.3%-3.6%
EPS (Basic)7.779.579.270.20(2.91)
EPS (Diluted)7.609.489.220.20(2.91)
Weighted Avg Shares50.29M50.81M51.23M51.38M49.56M
Weighted Avg Shares (Diluted)51.43M51.3M51.45M51.63M49.56M

Charles River Laboratories International, Inc.

NYSE:CRL

Intrinsic Alpha fair value

Locked

Current Price

$333.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.